Time- and radiation-dose dependent changes in the plasma proteome after total body irradiation of non-human primates: Implications for biomarker selection

Stephanie D. Byrum¹, Marie S. Burdine¹, Lisa Orr¹, Samuel G. Mackintosh¹, Simon Authier², Mylene Pouliot², Martin Hauer-Jensen³, Alan J. Tackett¹*

1 Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America, 2 CIToxLAB, Laval, Quebec, Canada, 3 Division of Radiation Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

* ajtackett@uams.edu

Abstract

Acute radiation syndrome (ARS) is a complex multi-organ disease resulting from total body exposure to high doses of radiation. Individuals can be exposed to total body irradiation (TBI) in a number of ways, including terrorist radiological weapons or nuclear accidents. In order to determine whether an individual has been exposed to high doses of radiation and needs countermeasure treatment, robust biomarkers are needed to estimate radiation exposure from biospecimens such as blood or urine. In order to identify such candidate biomarkers of radiation exposure, high-resolution proteomics was used to analyze plasma from non-human primates following whole body irradiation (Co-60 at 6.7 Gy and 7.4 Gy) with a twelve day observation period. A total of 663 proteins were evaluated from the plasma proteome analysis. A panel of plasma proteins with characteristic time- and dose-dependent changes was identified. In addition to the plasma proteomics study reported here, we recently identified candidate biomarkers using urine from these same non-human primates. From the proteomic analysis of both plasma and urine, we identified ten overlapping proteins that significantly differentiate both time and dose variables. These shared plasma and urine proteins represent optimal candidate biomarkers of radiation exposure.

Introduction

In today’s society, there is a distinct threat of terrorist attacks from chemical, biological, radiological, and/or nuclear weapons. Populations that are exposed to high radiation doses develop acute radiation syndrome (ARS), an acute illness caused by whole body exposure to a high dose of penetrating radiation over a short interval. Exposure to high ionizing radiation levels is associated with a wide range of biological effects including damage to macromolecules (e.g., DNA, proteins and lipids), increased mitochondria-dependent generation of reactive oxygen species (ROS), apoptosis, stress-related responses, and defects in the ability of cells to divide.
properly leading to an onset of symptoms. The range and severity of symptoms are dose dependent where lower doses tend to affect the hematopoietic system and gastrointestinal tract, while higher doses can result in cardiovascular and neurological effects and rapid death. Cell death from radiation is directly proportional to the mitotic rate and indirectly proportional to the cell’s state of differentiation. Areas of the body most affected by total body irradiation include the hematopoietic system, intestines, skin, spermatogenic cells and vascular system.

To effectively use existing therapies and even design new drugs as radiation countermeasures, suitable biomarkers that can be used to quantify radiation exposure (time and dose) are essential. Readily accessible biological samples for biomarker detection include urine and plasma [1]. A recent study compared the ability of plasma and urine to serve as sources of biomarkers for acute kidney injury (AKI) and concluded that the biomarkers identified in plasma had better discriminative power for preoperative risk stratification and early postoperative detection of AKI [2]. Our group previously reported a set of significantly differentiating urine proteins identified by high-resolution mass spectrometry from a study of twenty-four Rhesus macaque animals exposed to two different levels of gamma-irradiation (Co-60 at 6.7 Gy and 7.4 Gy) with a twelve day observation period [3]. In the current study, we examined the plasma from the same animals and identified a series of complementary biomarkers of radiation exposure. The overlapping plasma and urine candidate biomarkers are the first identified panel of putative biomarkers of radiation exposure in the Rhesus macaque model, which has immediate implications for human health and potential application in biodosimetry.

Materials and methods

Animals

The animals used in this study have been previously reported by Byrum et al. 2016 [3]. Briefly, the Rhesus monkey was selected for the study due to the fact it is a well characterized model for ARS and is the most commonly studied animal in radiation research under the US FDA Animal Rule. Procedures involving the care and use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) prior to conduct. During this study the care and use of animals were conducted in accordance with the principles outlined in the current Guidelines. The contract research organization (CRO) conducting the study was and is accredited by AAALAC.

There were 24 animals included in the study, which consisted of 4 animals per radiation dose (0, 6.7, and 7.4 Gy) and day of necropsy (day 4 and day 7). There were only 2 animals per radiation dose (6.7 and 7.4 Gy) for necropsy day 12. In accordance to historical data from irradiated and control animals, we selected radiation levels of 6.7 Gy and 7.4 Gy to cause significant GI-injury while insuring survival of some animals out to 12 days post-irradiation. The days 4 and 7 represent the time points for major GI-injury, while day 12 is a later endpoint to investigate GI-injury repair. Whole-body irradiation was performed as previously described. In brief, the animals were exposed to a single uniform total body dose of gamma radiation from a Co—60 source (Theratron1000) at a dose rate of approximately 60 cGy/min for 12 minutes.

Animal numbers were selected based on the planned statistical analyses, assuming that all responses analyzed will be approximately normally distributed. With 4 animals per dose group on necropsy days 4 and 7, and 2 animals per dose group on necropsy day 12, there will be approximately 80% power to detect dose and time effects with a significance level of 5%, assuming differences of 1 standard deviation in responses between adjacent doses and between adjacent necropsy days.

Competing interests: The authors have declared that no competing interests exist.
All animals were monitored throughout the study period. Clinical observations were recorded on all animals twice daily until Day 3 and 4 times daily from Day 4 to 12 (at least every 6 hours). Clinical observations included particular attention to infections, hemorrhage, mucositis, diarrhea, emesis, and individual food intake. A detailed clinical examination was performed on each animal prior to animal assignment, prior to irradiation and every 3 days thereafter, including the day of irradiation (prior to irradiation) and prior to necropsy.

Room environments were controlled and continuously monitored to maintain air temperature, relative humidity, consistent light dark cycles, and 10–15 air changes per hour. All animals were housed individually in stainless steel monkey cages equipped with an automatic watering system. Municipal tap water (which was exposed to ultraviolet light and purified by reverse osmosis) were provided to the animals *ad libitum*, except during designated procedures, via an automatic watering system or water bottles. A standard certified commercial chow (Harlan Teklad Certified Hi-Fiber Primate Diet #7195C) was provided to the animals twice daily and removed overnight prior to irradiation. Treats or fresh fruits/vegetables were provided as part of the animal enrichment program.

To minimize distress, all animals were given an acclimation period of at least 1 week following their arrival to the facility and prior to the start of irradiation. Animals were also acclimated the radiotherapy chair and transportation process. Positive reinforcement consisting of non-human primate treats and/or fruit juice were utilized to facilitate acclimation. The Clinical Veterinarian monitored all animal health assessments. In the event an animal became ill, supportive care would be offered for the following indications: 1.) pain, 2.) weight loss >15% of body weight, 3.) dehydration, 4.) fever, and/or 5.) bacterial infection.

Protocols were in place that allowed for the early euthanasia of animals in unrelievable pain or distress. Clinical criteria for premature euthanasia were: 1.) respiratory distress, 2.) anorexia (for at least 3 days), 3.) weight loss in excess of 20% of body weight, 4.) unresponsiveness, 5.) acute blood loss (>10% overall estimated blood volume), 6.) seizure activity, and 7.) abnormal appearance. Animals were to be euthanized if one of the above criteria were met. Euthanasia procedures were the same for animals prematurely euthanized or euthanized at specified study endpoints. For euthanasia, the animals were sedated with an intramuscular injection of a combination of ketamine hydrochloride and acepromazine, and then euthanized by an intravenous overdose of sodium pentobarbital, followed by exsanguination. There were no illnesses, premature deaths, or early euthanasia of any animals in the study.

**Plasma collection**

The 24 *Rhesus macaque* plasma samples included in this study correspond directly with the previously published urine samples [3]. Venous samples were observed from a peripheral vein (i.e. femoral or cephalic veins). Each blood sample was collected into tubes containing K2 EDTA as anticoagulant and kept on wet ice pending centrifugation. Within 30 minutes of collection, blood samples were centrifuged under refrigeration (set to +4˚C at 1500 g RCF) for targeted 10 minutes. Plasma was transferred into 4 separate tubes, placed on dry ice pending storage in a freezer set to -70˚C.

**High-resolution proteomics**

The top 20 most abundant proteins (albumin, IgG, transferrin, fibrinogen, IgA, α2-Macroglobulin, IgM, α1-Antitrypsin, complement C3, haptoglobin, apolipoprotein A1, A3 and B; α1-Acid Glycoprotein, ceruloplasmin, complement C4, C1q; IgD, prealbumin, and plasminogen) in the plasma were removed using the ProteoPrep 20 Plasma Immunodepletion Kit (Sigma-Aldrich, PROT20). Twenty micrograms of protein from depleted plasma was resolved
by 4–20% Tris-Glycine SDS-PAGE (Life Technologies) and the proteins were visualized by Coomassie-staining (Fig 1A). Each gel lane was sliced into 20 bands 2 mm in size. Gel bands were destained (50% methanol, 100 mM ammonium bicarbonate), followed by treatment with 10 mM Tris[2-carboxyethyl] phosphine to reduce protein disulfide bonds and 50 mM iodoacetamide to block reformation of cysteine disulfide bonds. Gel slices were then dehydrated in acetonitrile, followed by addition of 100 ng porcine sequencing grade modified trypsin in 100 mM ammonium bicarbonate and incubated at 37°C for 12–16 hours. Peptide products were then acidified in 0.1% formic acid. Tryptic peptides were separated by reverse phase Jupiter Proteo resin (Phenomenex) on a 100 × 0.075 mm column using a nanoAcquity UPLC system (Waters). Peptides were eluted using a 40 min gradient from 97:3 to 35:65 buffer A:B ratio. [Buffer A = 0.1% formic acid, 0.5% acetonitrile; buffer B = 0.1% formic acid, 75% acetonitrile]. Eluted peptides were ionized by electrospray (1.9 kV) followed by MS/MS analysis using collision induced dissociation on an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific). MS data were acquired using the FTMS analyzer in profile mode at a resolution of 60,000 over a range of 375 to 1500 m/z. MS/MS data were acquired for the top 15 peaks from each MS scan using the ion trap analyzer in centroid mode and normal mass range with normalized collision energy of 35.0.

Data analysis

Proteins were identified as reported in Byrum et al. 2016 [3]. The mass spectrometric raw data was analyzed by MaxQuant using a label-free intensity based approach. Proteins were identified by searching against the UniProtKB database (2015_06 release; restricted to Rhesus macaque; 69,970 entries). The MS1 intensities were normalized by using the intensity-based absolute quantification (iBAQ) method implemented in MaxQuant [4, 5]. Quantitative testing was performed in Scaffold Q+Q using iBAQ normalized intensity values to detect differential presence of a protein between different samples (time-dependent: days 4, 7, and 12 for both radiation doses 6.7 Gy and 7.4 Gy; dose-dependent: non-irradiated, 6.7 Gy, and 7.4 Gy from days 4, 7, and 12). Proteins were tested for significance by Kruskal-Wallis with Benjamini-Hochberg correction in a time and dose dependent manner. Proteins in the time dependent analysis were considered to be significant at p < 0.00509 and p < 0.00653 (corrected Benjamini-Hochberg p-value) for dose levels 6.7 Gy and 7.4 Gy gamma-irradiation exposure. Proteins in the dose-dependent analysis were considered to be significant at p < 0.00179, p < 0.00622, and p < 0.00525 (corrected Benjamini-Hochberg p-value) for days 4, 7, and 12 post-irradiation. The log2 normalized intensity values for each data comparison were visualized by Hierarchical Clustering Explorer (HCE 3.0). The hierarchical clusters were constructed using the average linkage method with Euclidean distance measure in order to cluster the significant proteins and visually inspect trends in the data. Significant proteins were analyzed for pathway expression using QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity). Scaffold files from urine (data from [3]) and plasma proteomes were used to identify the total number of proteins found in both body fluids as well as proteins significantly differentiating all sample groups by the Analysis of Variance with normalization by iBAQ and multiple test correction by Benjamini-Hochberg using Scaffold’s Quantitative Analysis tool. Raw data used for all calculations can be found in S1 and S2 Tables.

Results

We investigated changes in plasma proteome in response to total body gamma-irradiation in 24 Rhesus macaque. The plasma was collected and the top 20 most abundant plasma proteins were depleted prior to SDS-PAGE and mass spectrometric analysis (Fig 1A). Using MaxQuant and Scaffold programs, we identified a total of 663 proteins (338,187 spectra) from all 24
samples with a 95% protein probability, a minimum number of peptides of 2, and a 50% peptide probability threshold. The total number of identified proteins from each sample group is displayed in Venn diagrams for both time-dependent and dose-dependent analyses (Fig 1B & 1C). In the time-dependent analysis the number of proteins uniquely identified in the plasma samples was greatest at day 7 (68 proteins) with 6.7 Gy radiation exposure as compared with the higher dose of radiation in which the majority of uniquely identified proteins were identified on day 4 (75 proteins) (Fig 1B). In addition the dose-dependent analysis also shows the majority of uniquely identified proteins are found at day 7 (48 proteins) for the 6.7 Gy exposure but are identified at day 4 (20 proteins) for the 7.4 Gy gamma-irradiation exposure. This indicates more unique proteins are released in the blood due to gamma-irradiation damage at an earlier time point with the higher radiation dose level. These data suggest that certain windows of time have a greater probability for detection of plasma biomarkers of radiation exposure, and that with increasing dose these windows of time are closer to the time of exposure.

A label-free mass spectrometric workflow was used to measure relative levels of the proteins identified among the samples. The non-irradiated samples collected on day 4 served as a baseline control and were compared with both 6.7 Gy and 7.4 Gy gamma-irradiated animals for
Table 1. Significantly differentiating proteins from days 4, 7, and 12 at both gamma-irradiation doses of 6.7 Gy and 7.4 Gy.

| 6.7 Gy | 7.4 Gy |
|-------|-------|
| Identified Proteins | Accession Number | p-value | Identified Proteins | Accession Number | p-value |
| Alpha-1-antichymotrypsin | F6SL79 | 0.0001 | Alpha-1-antichymotrypsin | F6SL79 | 0.0002 |
| Alpha-1-antitrypsin | F6SEN6 | 0.0001 | Alpha-2-macroglobulin | G7N5X8 | 0.0001 |
| Alpha-2-macroglobulin | G7N5X8 | 0.0001 | Amine oxidase | G7NIT9 | 0.0001 |
| Annexin | F7H0C7 | 0.0001 | Fibrinectin isoform 4 preproprotein | H9YY12 | 0.0001 |
| Antithrombin III | A0N066 | 0.0001 | Putative uncharacterized protein | G7N9H7 | 0.0001 |
| Apolipoprotein A-I | APOA1 | 0.0001 | Putative uncharacterized protein | G7MJR4 | 0.0001 |
| Fibrinogen alpha chain | F6UZ60 | 0.0001 | Putative uncharacterized protein | G7NQN4 | 0.0001 |
| Fibrinectin isoform 4 preproprotein | H9YY12 | 0.0001 | Putative uncharacterized protein | G7MT40 | 0.0001 |
| Plasminogen | F7CC91 | 0.0001 | Transferin | A0A0A7RQ61 | 0.0001 |
| Putative uncharacterized protein | G7N9H7 | 0.0001 | Uncharacterized protein (Fragment) | F6XU42 | 0.0001 |
| Putative uncharacterized protein | G7M63 | 0.0001 | Uncharacterized protein | F6TNV9 | 0.0001 |
| Putative uncharacterized protein | G7NQN4 | 0.0001 | Uncharacterized protein | F7CEU1 | 0.0001 |
| Putative uncharacterized protein | G7MT40 | 0.0001 | Uncharacterized protein | F6WDG6 | 0.0001 |
| Putative uncharacterized protein | G7M63 | 0.0001 | Uncharacterized protein | F6UZ87 | 0.0001 |
| Transferin | A0A0A7RQ61 | 0.0001 | Uncharacterized protein | F7FHV9 | 0.0001 |
| Uncharacterized protein (Fragment) | F6XU42 | 0.0001 | Uncharacterized protein | F6Z0R5 | 0.0001 |
| Uncharacterized protein | F6TNV9 | 0.0001 | Uncharacterized protein | F6Y7Q4 | 0.0001 |
| Uncharacterized protein | F7HM15 | 0.0001 | Uncharacterized protein | F6X9G9 | 0.0001 |
| Uncharacterized protein | F7CEU1 | 0.0001 | Uncharacterized protein | F6TI3 | 0.0001 |
| Uncharacterized protein | F6UZ87 | 0.0001 | Putative uncharacterized protein | G7MJU4 | 0.0002 |
| Uncharacterized protein | F6UY8 | 0.0001 | Alpha-1-antichymotrypsin | F6SL79 | 0.0002 |
| Uncharacterized protein | F7FHV9 | 0.0001 | Coagulation factor X protein | A0N065 | 0.0002 |
| Uncharacterized protein | F6Z0R5 | 0.0001 | Uncharacterized protein | F6X837 | 0.0002 |
| Uncharacterized protein | F6Y7Q4 | 0.0001 | Uncharacterized protein | F7DAU3 | 0.0002 |
| Uncharacterized protein | F6X9G9 | 0.0001 | Uncharacterized protein | F7GHV1 | 0.0002 |
| Uncharacterized protein | F6TI3 | 0.0001 | Uncharacterized protein | F7HM15 | 0.0003 |
| Vinculin isoform VCL | I0FH43 | 0.0001 | Uncharacterized protein | F7AB32 | 0.0003 |
| Uncharacterized protein | F7HP23 | 0.00024 | C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 | G7NG17 | 0.0003 |
| Complement C1r subcomponent | H9FZ50 | 0.00046 | Prothrombin | A0N064 | 0.0007 |
| Gelsolin isoform a | H9Z838 | 0.0011 | Coagulation factor IX protein | A8CZ27 | 0.0013 |
| Putative uncharacterized protein | G7NH09 | 0.0013 | Annexin | F7H0C7 | 0.0014 |
| Annexin | F7D2H1 | 0.0019 | Putative uncharacterized protein | G7N9H9 | 0.0015 |
| Uncharacterized protein | F6WYB6 | 0.0022 | Cytokeratin-1 | F7B786 | 0.0017 |
| Uncharacterized protein | F7HS32 | 0.0023 | Collagen alpha-2(I ) chain | H9Z2D1 | 0.002 |
| Angiotensinogen preproprotein | G7MFR4 | 0.0027 | Uncharacterized protein | F7HP23 | 0.0021 |
| Putative; complement C4-A isoform 1 (Fragment) | H9FF97 | 0.0028 | Interacellular adhesion molecule 1 | G7NKZ5 | 0.0022 |
| Putative uncharacterized protein | G7M63 | 0.0031 | Putative uncharacterized protein | G7MFA4 | 0.0025 |
| Uncharacterized protein | F6TLR3 | 0.0045 | Putative uncharacterized protein | G7NX1 | 0.0032 |
| | | | Uncharacterized protein | F6UR30 | 0.0034 |
| | | | Desmoplakin-3 | F7H7V0 | 0.0036 |
| | | | Gelsolin isoform a | H9Z838 | 0.004 |
| | | | Uncharacterized protein | F6YKA7 | 0.0045 |
| | | | Antithrombin III | A0N066 | 0.0047 |
| | | | Complement C1r subcomponent | H9FZ50 | 0.005 |

(Continued)
three post-irradiation time points (days 4, 7, and 12). The proteins were identified using MaxQuant and normalized by iBAQ. The \( \log_2 \) normalized intensity values were then analyzed using Kruskal-Wallis with Benjamini-Hochberg multiple test correction for each comparison. Proteins that were found to be significant after p-value correction are listed in Tables 1 and 2. The iBAQ normalized intensity values for all proteins and all samples are listed in S1 Table. Hierarchical cluster heat maps were generated using the \( \log_2 \) normalized intensity values to visually inspect trends in the data from the significantly differentiating proteins in a time-dependent and dose-dependent analysis (Figs 2 and 3). The heat maps show clear differences in protein levels from each comparison. Fig 2 shows the significant proteins from the time-dependent analysis and reveals a trend of proteins changing levels from day 4 to day 12 post-irradiation. For both radiation doses, several protein level changes are observed by day 4. In the dose-dependent analysis, the 6.7 and 7.4 Gy exposures show proteins changing in levels starting on day 4 and continuing through day 12 (Fig 3).

Interestingly, pathway analysis revealed possible liver and intestinal damage as a consequence of gamma-irradiation (Tables 3 and 4). The LXR/RXR activation pathway is significantly activated at days 4 (4 proteins), 7 (9 proteins), and 12 (7 proteins) post-irradiation with the majority of proteins identified at day 7. LXR/RXR (liver X receptor/retinoid X receptor ligands) activation pathway has been shown previously in human intestinal cell line CaCo-2 to increase the efflux of cholesterol and plays an important role in intestinal HDL production and cholesterol absorption [6]. The liver X receptors are important regulators that control the genes involved in efflux and excretion of cholesterol and lipid homeostasis in tissues including the liver, intestine, and brain [7]. Evidence for the increased activation of these receptors indicates possible liver and intestinal damage due to gamma-irradiation. In addition, the FXR/RXR activation pathway plays a role in regulating metabolic pathways and also leads to efflux and secretion of cholesterol and was found to be activated at day 7 post-irradiation [8]. Evidence also supports the role of FXR (farnesoid X receptor) in the reduction of proinflammatory cytokines in the intestinal tract preventing inflammation and epithelial permeability [9]. The acute phase response pathway is activated for all time points and dose levels and is involved in the response to tissue injury, infection, or inflammation as well as the restoration of homeostasis [10]. Clathrin-mediated endocytosis was found to be significantly activated at day 12 post-irradiation and is involved in the clearance of LDL from the blood stream through endocytosis. Clathrin-coated vesicles form domains of the plasma membrane and are responsible for receptor-mediated endocytosis of ligands such as low density lipoprotein (LD), transferrin, growth factors, and more [11, 12]. The coagulation system and extrinsic and intrinsic prothrombin activation pathways are activated in response to vasculature damage such as bleeding and thrombosis. These pathways work in balance with one another and were identified as up-regulated at different time points and dose levels [13] (Tables 3 and 4).

### Table 1. (Continued)

| 6.7 Gy Identified Proteins Accession Number | 7.4 Gy Identified Proteins Accession Number | p-value | p-value |
|--------------------------------------------|--------------------------------------------|---------|---------|
| Cytokeratin-6C G7N720 0.0054               | Uncharacterized protein (Fragment) F7HD19 0.0058 |

Proteins were considered significant with p-values less than the Kruskal-Wallis Benjamini-Hochberg corrected values (p < 0.00509 and p < 0.00653 for dose levels 6.7 Gy and 7.4 Gy).

https://doi.org/10.1371/journal.pone.0174771.t001
| Day 4 | Day 7 | Day 12 |
|-------|-------|--------|
| Identified Proteins | Accession Number | p-value | Identified Proteins | Accession Number | p-value | Identified Proteins | Accession Number | p-value |
| Alpha-2-macroglobulin | G7N5X8 | 0.0001 | Alpha-2-macroglobulin | G7N5X8 | 0.0001 | Alpha-2-macroglobulin | G7N5X8 | 0.0001 |
| Fibrinogen alpha chain | F6UZ60 | 0.0001 | Amine oxidase | G7NIT9 | 0.0001 | Apolipoprotein A-I | APOA1 | 0.0001 |
| Plasminogen | F7CC91 | 0.0001 | Annexin | F7H0C7 | 0.0001 | Fibrinogen alpha chain | F6UZ60 | 0.0001 |
| Putative uncharacterized protein | G7N9H7 | 0.0001 | Apolipoprotein A-I | APOA1 | 0.0001 | Fibronectin isoform 4 preproprotein | H9YY12 | 0.0001 |
| Putative uncharacterized protein | G7MRJ4 | 0.0001 | Desmoplakin-3 | F7H7V0 | 0.0001 | Putative uncharacterized protein | G7N9H7 | 0.0001 |
| Putative uncharacterized protein | G7NQN4 | 0.0001 | Putative uncharacterized protein | G7N9H7 | 0.0001 | Putative uncharacterized protein | G7MRJ4 | 0.0001 |
| Putative uncharacterized protein | G7MT40 | 0.0001 | Putative uncharacterized protein | G7MRJ4 | 0.0001 | Putative uncharacterized protein | G7NQN4 | 0.0001 |
| Putative uncharacterized protein | G7MS63 | 0.0001 | Putative uncharacterized protein | G7NQN4 | 0.0001 | Putative uncharacterized protein | G7MT40 | 0.0001 |
| Transferrin | A0A0A7RQ61 | 0.0001 | Putative uncharacterized protein | G7MT40 | 0.0001 | Putative uncharacterized protein | G7MS63 | 0.0001 |
| Uncharacterized protein (Fragment) | F6XU42 | 0.0001 | Transferrin | A0A0A7RQ61 | 0.0001 | Transferrin | A0A0A7RQ61 | 0.0001 |
| Uncharacterized protein | F6TNV9 | 0.0001 | Uncharacterized protein (Fragment) | F6XU42 | 0.0001 | Uncharacterized protein (Fragment) | F6XU42 | 0.0001 |
| Uncharacterized protein | F7CEU1 | 0.0001 | Uncharacterized protein | F6TNV9 | 0.0001 | Uncharacterized protein | F6TNV9 | 0.0001 |
| Uncharacterized protein | F6UZ87 | 0.0001 | Uncharacterized protein | F7HM15 | 0.0001 | Uncharacterized protein | F7HM15 | 0.0001 |
| Uncharacterized protein | F6Z0R5 | 0.0001 | Uncharacterized protein | F7CEU1 | 0.0001 | Uncharacterized protein | F7CEU1 | 0.0001 |
| Alpha-1-antichymotrypsin | F6SL79 | 0.0001 | Uncharacterized protein | F6WDG6 | 0.0001 | Uncharacterized protein | F6UZ87 | 0.0001 |
| Collagen alpha-2(I) chain | H9Z2D1 | 0.0001 | Uncharacterized protein | F6Z0R5 | 0.0001 | Uncharacterized protein | F6UYY8 | 0.0001 |
| Uncharacterized protein | F7GHV1 | 0.0001 | Uncharacterized protein | F6Y7Q4 | 0.0001 | Uncharacterized protein | F7FHV9 | 0.0001 |
| Uncharacterized protein | F7HP23 | 0.0011 | Vinculin isoform VCL | I0FH43 | 0.0001 | Uncharacterized protein | F6Z0R5 | 0.0001 |
| Antithrombin III | A0N066 | 0.0012 | Uncharacterized protein | F7FHV9 | 0.00011 | Uncharacterized protein | F6Y7Q4 | 0.0001 |
| | | | Putative uncharacterized protein | G7N9X1 | 0.00022 | Uncharacterized protein | F6X9G9 | 0.0001 |
| | | | Uncharacterized protein | F6TI13 | 0.00023 | Uncharacterized protein | F6TI13 | 0.0001 |
| | | | Uncharacterized protein | F6X9G9 | 0.00026 | Prothrombin | A0N064 | 0.00019 |
| | | | Complement C1r subcomponent | H9FZ50 | 0.00027 | Uncharacterized protein | F7HP23 | 0.00024 |

(Continued)
Table 2. (Continued)

| Identified Proteins | Accession Number | p-value | Identified Proteins | Accession Number | p-value | Identified Proteins | Accession Number | p-value |
|---------------------|------------------|---------|---------------------|------------------|---------|---------------------|------------------|---------|
| Uncharacterized protein | F6X837          | 0.00035 | Gelsolin isoform a  | H9Z838          | 0.00047 |
| Antithrombin III | A0N066          | 0.00053 | Putative uncharacterized protein (Fragment) | G7N2L0          | 0.0007 |
| Putative uncharacterized protein | G7MJU4         | 0.0006  | Alpha-1-antichymotrypsin | F6SL79        | 0.00088 |
| Fibronectin isoform 4 preproprotein | H9YY12        | 0.00066 | Putative uncharacterized protein | G7NH09         | 0.0012 |
| Putative uncharacterized protein | G7NH09         | 0.00077 | Putative: complement C4-A isoform 1 (Fragment) | H9FF97         | 0.0012 |
| Alpha-amylase | G7MIC0          | 0.00091 | Uncharacterized protein | F7D6T8         | 0.0012 |
| Uncharacterized protein | F6SSW9         | 0.0011  | Apolipoprotein(a) (Fragment) | APOA           | 0.0015 |
| Alpha-1-antitrypsin | F6SEN6         | 0.0012  | Uncharacterized protein | F7AB32         | 0.0019 |
| Cofilin-1 | I0FG05          | 0.0013  | Apolipoprotein(a) (Fragment) | F7FPV8         | 0.0021 |
| Uncharacterized protein | F6UZ87         | 0.0016  | Alpha-albumin (Fragment) | G7MT38         | 0.0024 |
| Thioredoxin | F6RHG3          | 0.0017  | Putative uncharacterized protein | G7MJU4         | 0.0026 |
| Coagulation factor X protein | A0N065        | 0.0018  | Uncharacterized protein (Fragment) | H9H2V9         | 0.0033 |
| Cytokeratin-6C | G7N720          | 0.0018  | Annexin | F7D2H1          | 0.0036 |
| Putative uncharacterized protein | G7N2G0        | 0.0019  | 14-3-3 protein zeta/ delta | F7EFF6        | 0.0037 |
| Talin-1 | G7NFD2          | 0.0019  | Amine oxidase | G7NIT9         | 0.0038 |
| Uncharacterized protein | F6YKA7        | 0.0019  | Uncharacterized protein | F6VZJ5        | 0.0044 |
| Alpha-amylase | F7H0E4          | 0.002   | Complement C3 | H9EXI6         | 0.0025 |
| Complement C3 | I2CT48          | 0.0035  | Angiotensinogen preproprotein | G7MFR4        | 0.0027 |
| Cytokeratin-1 | F7B786          | 0.0031  | Coagulation factor IX protein | A8C2Z27       | 0.0027 |
| Uncharacterized protein | F6TLR3        | 0.0034  | Cytokeratin-1 | F7D2H1        | 0.0037 |
| Complement C3 | I2CT48          | 0.0035  | Annexin | F7D2H1         | 0.0037 |
| Glutathione S-transferase P | GSTP1         | 0.0037  | Tropomyosin beta chain isoform 1 | F7GSX6        | 0.0038 |
| Uncharacterized protein | F7HP23         | 0.0041  | (Continued) |
Table 2. (Continued)

| Day 4 | Identified Proteins | Accession Number | p-value | Day 7 | Identified Proteins | Accession Number | p-value | Day 12 | Identified Proteins | Accession Number | p-value |
|-------|---------------------|------------------|---------|-------|---------------------|------------------|---------|--------|---------------------|------------------|---------|
|       | Putative uncharacte\rzized protein (Fragment) | G7N2L0 | 0.0054 |       | Uncharacterized protein | F6SGB4 | 0.0054 |       | Uncharacterized protein | F7GSK8 | 0.0056 |

Proteins were considered significant with p-values less than the Kruskal-Wallis Benjamini-Hochberg corrected values (p < 0.00179, p < 0.00622, and p < 0.00525 for days 4, 7, and 12).

https://doi.org/10.1371/journal.pone.0174771.t002

Fig 2. Hierarchical cluster of significantly differentiating proteins in a time dependent manner at 6.7 Gy (A) and 7.4 Gy (B) gamma-irradiation exposures. Proteins were clustered using the average linkage method and Euclidean distance metric. Proteins were considered significant by Kruskal-Wallis p-value corrected using Benjamini-Hochberg. Red indicates elevated levels, while blue indicates lower levels of the given protein.

https://doi.org/10.1371/journal.pone.0174771.g002
Fig 3. Hierarchical cluster of significantly differentiating proteins in a dose dependent manner from days 4 (A), 7 (B), and 12 (C) post-irradiation. Proteins were clustered using the average linkage method and Euclidean distance metric. Proteins were considered significant by Kruskal-Wallis p-value corrected using Benjamini-Hochberg. Red indicates elevated levels, while blue indicates lower levels of the given protein. 

https://doi.org/10.1371/journal.pone.0174771.g003

Table 3. Time-dependent analysis.

| Pathway                                 | Dose: 6.7 Gy |                 | Dose: 7.4 Gy |                |
|-----------------------------------------|--------------|----------------|--------------|----------------|
|                                         | p-value      | Overlap        | p-value      | Overlap        |
| Acute Phase Response Signaling          | 4.98E-23     | 14/169         | 9.97E-15     | 10/169         |
| Clathrin-mediated Endocytosis Signaling | 9.82E-11     | 8/197          | 1.99E-07     | 6/197          |
| Coagulation System                      | 5.41E-17     | 8/35           | 4.97E-12     | 6/35           |
| Extrinsic Prothrombin Activation Pathway| 4.53E-09     | 8/126          |              | 4/16           |
| FXR/RXR Activation                      | 2.68E-12     | 8/126          |              | 4/16           |
| Intrinsic Prothrombin Activation Pathway| 1.46E-12     | 8/126          |              | 6/29           |
| LXR/RXR Activation                      | 1.93E-12     | 8/121          |              | 6/29           |

The top 5 canonical pathways identified by IPA from proteins significantly differentiating between days 4, 7, and 12 post-irradiation. The pathway p-values are calculated using the right-tailed Fisher Exact Test. The complete list of pathways can be found in S3 Table.

https://doi.org/10.1371/journal.pone.0174771.t003
The plasma data reported here show a remarkably similar trend to what was previously reported for the analysis of urine from the same Rhesus macaque animals [3]. The data reported also show the importance to study the kinetics of plasma proteins change in level across doses of radiation tested (Figs 2 & 3). Furthermore, unique proteins present in the plasma are more readily detected at earlier time points for higher radiation exposures (Fig 1). Specifically, 7.4 Gy produces more unique proteins at day 4, while 6.7 Gy produces the most unique proteins at day 7. Higher radiation levels are expected to induce more severe changes which appear to translate into earlier characteristic changes to the proteome. Moreover, in the analysis of the urine from the same animals [3], the higher radiation dose (7.4 Gy) resulted in the most unique proteins on day 4 compared to the lower radiation dose (6.7 Gy) in which unique proteins were at the highest level on day 7. These results differ from the radiation dose-

| Pathway                                | Day 4         | Day 7         | Day 12        |
|----------------------------------------|---------------|---------------|---------------|
|                                        | p-value       | Overlap       | p-value       | Overlap       | p-value       | Overlap       |
| Actin Cytoskeleton Signaling            | 1.29E-10      | 9/228         | 8.10E-18      | 11/169        |
| Acute Phase Response Signaling         | 1.83E-14      | 8/169         | 1.83E-13      | 10/169        | 3.38E-13      | 9/197         |
| Clathrin-mediated Endocytosis Signaling| 1.21E-11      | 5/35          | 1.51E-13      | 7/35          | 3.12E-10      | 5/35          |
| Coagulation System                     | 1.03E-07      | 3/16          | 6.13E-13      | 4/126         |
| Extrinsic Prothrombin Activation Pathway| 2.07E-09      | 4/29          |              |              |
| FXR/RXR Activation                     | 7.17E-07      | 4/121         | 4.23E-13      | 9/121         | 3.98E-11      | 7/121         |

The top 5 canonical pathways identified by IPA from proteins significantly differentiating between 6.7 Gy and 7.4 Gy gamma-irradiation dose levels. The pathway p-values are calculated using the right-tailed Fisher Exact Test.

https://doi.org/10.1371/journal.pone.0174771.t004

Discussion

The plasma data reported here show a remarkably similar trend to what was previously reported for the analysis of urine from the same Rhesus macaque animals [3]. The data reported also show the importance to study the kinetics of plasma proteins change in level across doses of radiation tested (Figs 2 & 3). Furthermore, unique proteins present in the plasma are more readily detected at earlier time points for higher radiation exposures (Fig 1). Specifically, 7.4 Gy produces more unique proteins at day 4, while 6.7 Gy produces the most unique proteins at day 7. Higher radiation levels are expected to induce more severe changes which appear to translate into earlier characteristic changes to the proteome. Moreover, in the analysis of the urine from the same animals [3], the higher radiation dose (7.4 Gy) resulted in the most unique proteins on day 4 compared to the lower radiation dose (6.7 Gy) in which unique proteins were at the highest level on day 7. These results differ from the radiation dose-

Fig 4. Venn diagrams show overlapping proteins identified in both plasma and urine samples from gamma-irradiated non-human primates. A) Total proteins identified in both sample types. B) From the 414 commonly identified proteins between plasma and urine, the Venn diagram shows how many were found to be significant in each sample type by ANOVA with a p-value < 0.05. Ten proteins are identified as significant from both the plasma and urine proteomic analyses.

https://doi.org/10.1371/journal.pone.0174771.g004
dependent kinetics observed with citrulline for which higher radiation doses were associated with more pronounced changes at later time points [14]. The distinct kinetics of proteomic changes reported herein presents potential advantages for dosimetry applications for which an earlier assessment of exposure is critical to guide medical management. Results also suggest that the optimal time window for detection of unique proteins at each radiation dose tested is similar for the analysis of plasma and urine. A previous report using proteomics to analyze plasma from radiation accident victims identified different levels of six annotated proteins over 18 gel spots [15]; two of those six proteins were also mis-regulated in the current data set—fibrinogen alpha chain and transferrin.

We previously reported the identification of 2346 total proteins in urine and here we report the identification of 663 total proteins in the plasma of the same animals exposed to gamma irradiation. Of all the proteins identified in both data sets, 414 were found to be in common (Fig 4A). The Venn diagram in Fig 4B shows the number of proteins identified from both plasma and urine (414 proteins) that are also identified as significant by ANOVA (p-value < 0.05). From the list of common proteins identified in plasma and urine, 33 and 46 proteins were found to significantly change in abundance in the plasma and urine samples, respectively (Fig 4B). In addition, 10 proteins were found to significantly differentiate between both dose and time points in both plasma and urine from the same animals. These include angiotensinogen preproprotein (G7MFR4), ferritin (F6ZV45), uncharacterized proteins (F6TLR3, F7DHQ1, and F7GRY2), putative uncharacterized protein (G7NQN4 and G7MJ28), serum amyloid A (G7NDT1 and F7DY68), and angiotensin-converting enzyme isoform 1 (H9FJ99). According to UniProtKB database (www.uniprot.org), serum amyloid A is a major acute phase reactant and is the apolipoprotein of the HDL complex, uncharacterized protein F7GRY2 (C9) is involved in the immune response, and uncharacterized protein F7DHQ1 (CRP) regulates interleukin-8 secretion. Therefore, the shedding of these proteins into the plasma and urine indicate increased activity of the immune system in response to radiation exposure. The pathways involved include regulators of the efflux and secretion of cholesterol, clearance of LDL from the blood, and the coagulation system. These 10 proteins detected between the plasma and urine analyses are optimal candidates for further study as biomarkers of radiation exposure.

Supporting information
S1 Table. Normalized iBAQ intensity values. ANOVA analysis was performed in Scaffold Q+S. Proteins with a p-value < 0.05 are considered significantly different among the gamma-irradiation exposure levels and the days post-irradiation. (XLSX)

S2 Table. Raw data output from MaxQuant consisting of iBAQ, LFQ, and MS/MS count data. (XLSX)

S3 Table. IPA Canonical pathways by Dose and Time-dependent analysis. The pathway p-values are calculated using a right-tailed Fisher Exact test and are shown in the -log10 scale. (XLSX)

Acknowledgments
This project has been partially funded with Federal funds from the Office of the ASPR, BARDA under contract # HHSO100201100045C. The ideas presented are the authors and not those of the Government. Additional funding for this work has come from NIH grants
R01GM106024, R33CA173264, R21ES025268, UL1TR000039, P20GM103429, and P20GM109005. The mass spectrometric data was collected by the UAMS proteomics core facility.

**Author Contributions**

**Conceptualization:** SB MB LO SM SA MP MHJ AT.

**Data curation:** SB MB LO SM SA MP MHJ AT.

**Formal analysis:** SB MB LO SM SA MP MHJ AT.

**Funding acquisition:** MHJ AT.

**Investigation:** SB MB LO SM SA MP MHJ AT.

**Methodology:** SB MB LO SM SA MP MHJ AT.

**Project administration:** SB MB LO SM SA MP MHJ AT.

**Resources:** SB MB LO SM SA MP MHJ AT.

**Validation:** SB MB LO SM SA MP MHJ AT.

**Writing – original draft:** SB MB LO SM SA MP MHJ AT.

**Writing – review & editing:** SB MB LO SM SA MP MHJ AT.

**References**

1. Guipaud O. Serum and Plasma Proteomics and Its Possible Use as Detector and Predictor of Radiation Diseases. In: Leszczynski D, editor. Radiation Proteomics: The effects of ionizing and non-ionizing radiation on cells and tissues. Dordrecht: Springer Netherlands; 2013. p. 61–86.

2. Schley G, Köberle C, Manuilova E, Rutz S, Forster C, Weyand M, et al. Comparison of Plasma and Urine Biomarker Performance in Acute Kidney Injury. PLoS ONE. 2015; 10(12):e0145042. https://doi.org/10.1371/journal.pone.0145042 PMID: 26669323

3. Byrum SD, Burdine MS, Orr L, Moreland L, Mackintosh SG, Authier S, et al. A Quantitative Proteomic Analysis of Urine from Gamma-Irradiated Non-Human Primates. Journal of proteomics & bioinformatics. 2016; 9(Suppl 10):005.

4. Schwanhaußser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011; 473(7347):337–42. https://doi.org/10.1038/nature10098 PMID: 21593866

5. Krey JF, Wilmarth PA, Shin J-B, Klimek J, Sherman NE, Jeffery ED, et al. Accurate Label-Free Protein Quantitation with High- and Low-Resolution Mass Spectrometers. Journal of Proteome Research. 2014; 13(2):1034–44. https://doi.org/10.1021/pr401017h PMID: 24295401

6. Murthy S, Born E, Mathur SN, Field FJ. LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. Journal of Lipid Research. 2002; 43(7):1054–64. PMID: 12091489

7. Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014; 13(6):433–44. https://doi.org/10.1038/nrd4280 PMID: 24833295

8. Ding L, Pang S, Sun Y, Tian Y, Yu L, Dang N. Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes. International Journal of Endocrinology. 2014; 2014:13.

9. Stojanecvic M, Stanek K, Mikov M. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. Canadian Journal of Gastroenterology. 2012; 26(9):631–7. PMID: 22993736

10. Moshage H. Cytokines and the hepatic acute phase response. The Journal of Pathology. 1997; 181(3):257–66. https://doi.org/10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U PMID: 9155709

11. Marsh M, McMahon HT. The Structural Era of Endocytosis. Science. 1999; 285(5425):215–20. PMID: 10398591
12. Anderson RGW, Brown MS, Goldstein JL. Role of the coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblasts. Cell. 1977; 10(3):351–64. PMID: 191195

13. Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian Journal of Anaesthesia. 2014; 58(5):515–23. https://doi.org/10.4103/0019-5049.144643 PMID: 25535411

14. Bujold K, Hauer-Jensen M, Donini O, Rumage A, Hartman D, Hendrickson HP, et al. Citrulline as a Biomarker for Gastrointestinal-Acute Radiation Syndrome: Species Differences and Experimental Condition Effects. Radiation Research. 2016; 186(1):71–8. https://doi.org/10.1667/RR14305.1 PMID: 27351760

15. Nylund R, Lemola E, Hartwig S, Lehr S, Acheva A, Jahns J, et al. Profiling of low molecular weight proteins in plasma from locally irradiated individuals. Journal of Radiation Research. 2014; 55(4):674–82. https://doi.org/10.1093/jrr/rru007 PMID: 24570173